ORIGINE, 2012 trial summary

A randomised clinical trial investigating the effect of insulin glargine versus control in with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes

        Z

NCT00069784    N Engl J Med 2012;367:319-28  



Studied treatment insulin glargine (with a target fasting blood glucose level of ¡Ü95 mg per deciliter
Control treatment standard care
HbA1c contrast -0.3%



Patients with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes
Group sizes6264 / 6273
primary prevention
history of cardiovascular



Blindness Inclusion period
Follow-up duration 6.2 years Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI fatal and non fatal stroke - 6264 - 6273 1,03[0,88; 1,20] Nephropathy - 6264 - 6273 no data amputation - 6264 - 6273 0,89[0,60; 1,32] all causes death - 6264 - 6273 0,98[0,89; 1,07] Microvascular event - 6264 - 6273 0,97[0,90; 1,05] CV events - 6264 - 6273 1,02[0,94; 1,11] fatal and non fatal MI - 6264 - 6273 1,02[0,88; 1,19] Retinopathy - 6264 - 6273 no data Hospitalization for heart failure - 6264 - 6273 0,90[0,77; 1,05] CVdeath - 6264 - 6273 1,00[0,89; 1,13]0,22,01,0

Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28     [PMID: 22686416]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT00069784



Registering number NCT00069784 (see trial on clinicaltrials.gov)
Code Name